Stocks of the Hour: PainChek, Chimeric Therapeutics, Torque Metals
Stocks of the Hour: PainChek, Chimeric Therapeutics, Torque Metals
To register for Friday's webinar click here.
PainChek (ASX:PCK), developer of the world's first smart based pain assessment and monitoring application, has announced it has established a reseller agreement with Nourish Care, a leading UK care management software provider. The agreement has an initial 12-month term with an opportunity to renew by both parties and will facilitate sales of the PainChek digital pain assessment app. Shares are trading 3.45 per cent lower at 2.8 cents.
Chimeric Therapeutics (ASX:CHM) has highlighted recent successes and provided insight into key clinical catalysts for 2024. All 2023 milestones successfully accomplished establishing the foundation for multiple significant clinical catalysts in 2024. Shares are trading 3.45 per cent lower at 2.8 cents.
Torque Metals (ASX:TOR) has provided results from its reverse circulation ("RC") and Diamond drill campaign at the New Dawn Lithium Project. The results show consistent and impressive high-grade lithium results. Shares are trading flat at 16 cents.
To register for Friday's webinar click here.
要註冊參加週五的網絡研討會，請單擊此處。
PainChek (ASX:PCK), developer of the world's first smart based pain assessment and monitoring application, has announced it has established a reseller agreement with Nourish Care, a leading UK care management software provider. The agreement has an initial 12-month term with an opportunity to renew by both parties and will facilitate sales of the PainChek digital pain assessment app. Shares are trading 3.45 per cent lower at 2.8 cents.
全球首款基於智能的疼痛評估和監測應用程序的開發商PainChek（澳大利亞證券交易所股票代碼：PCK）宣佈已與英國領先的護理管理軟件提供商Nourish Care簽訂了經銷商協議。該協議的初始期限爲12個月，雙方都有機會續訂，並將促進PainChek數字疼痛評估應用程序的銷售。股價下跌3.45％，至2.8美分。
Chimeric Therapeutics (ASX:CHM) has highlighted recent successes and provided insight into key clinical catalysts for 2024. All 2023 milestones successfully accomplished establishing the foundation for multiple significant clinical catalysts in 2024. Shares are trading 3.45 per cent lower at 2.8 cents.
Chimeric Therapeutics（澳大利亞證券交易所股票代碼：CHM）重點介紹了最近取得的成功，並對2024年的關鍵臨床催化劑提供了見解。2023 年的所有里程碑都成功地完成了在 2024 年爲多種重要臨床催化劑奠定了基礎。股價下跌3.45％，至2.8美分。
Torque Metals (ASX:TOR) has provided results from its reverse circulation ("RC") and Diamond drill campaign at the New Dawn Lithium Project. The results show consistent and impressive high-grade lithium results. Shares are trading flat at 16 cents.
Torque Metals（澳大利亞證券交易所股票代碼：TOR）已經提供了其在新黎明鋰項目的反循環（“RC”）和鑽石鑽探活動的結果。結果顯示出一致且令人印象深刻的高等級鋰電池結果。股價持平至16美分。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧